The price of Viking Therapeutics Inc. (NASDAQ:VKTX) shares last traded on Wall Street fell -6.45% to $22.78.
Based on available information, 11 analysts follow Viking Therapeutics Inc. (NASDAQ:VKTX). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $40.00 and a low of $24.00, we find $34.00. Given the previous closing price of $24.35, this indicates a potential upside of 39.63 percent. VKTX stock price is now 25.98% away from the 50-day moving average and 156.23% away from the 200-day moving average. The market capitalization of the company currently stands at $2.30B.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
Among analysts, 0 rate the stock a hold while 10 rate it a buy. Brokers who have rated the stock have averaged $33.00 as their price target over the next twelve months.
.
In other news, Rowland Charles A Jr, Director sold 40,000 shares of the company’s stock on May 16. The stock was sold for $1,000,000 at an average price of $25.00. Upon completion of the transaction, the Director now directly owns 30,000 shares in the company, valued at $0.68 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 16, Director MACARTNEY LAWSON sold 16,000 shares of the business’s stock. A total of $384,000 was realized by selling the stock at an average price of $24.00. This leaves the insider owning 47,965 shares of the company worth $1.09 million. Insiders disposed of 1,657,159 shares of company stock worth roughly $37.75 million over the past 1 year. A total of 6.24% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in VKTX stock. A new stake in Viking Therapeutics Inc. shares was purchased by VIKING GLOBAL INVESTORS LP during the first quarter worth $44,536,000. WASATCH ADVISORS LP invested $38,850,000 in shares of VKTX during the first quarter. In the first quarter, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) acquired a new stake in Viking Therapeutics Inc. valued at approximately $25,628,000. RTW INVESTMENTS, LP acquired a new stake in VKTX for approximately $22,780,000. PERCEPTIVE ADVISORS LLC purchased a new stake in VKTX valued at around $19,858,000 in the second quarter. In total, there are 170 active investors with 35.70% ownership of the company’s stock.
A candlestick chart of Viking Therapeutics Inc. (NASDAQ: VKTX) showed a price of $24.48 on Tuesday morning. During the past 12 months, Viking Therapeutics Inc. has had a low of $2.02 and a high of $25.03. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 9.60, and a quick ratio of 9.60. The fifty day moving average price for VKTX is $18.33 and a two-hundred day moving average price translates $8.99 for the stock.
The latest earnings results from Viking Therapeutics Inc. (NASDAQ: VKTX) was released for Mar, 2023.
Viking Therapeutics Inc.(VKTX) Company Profile
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
